Polycystic ovary syndrome (PCOS) affects 8-13 per cent of Australian reproductive-aged women. It is a major public health concern with a significant undiagnosed burden of disease and reproductive, metabolic and psychological health consequences.
The diagnosis of PCOS remains challenging and controversial and several recognised phenotypes and variants exist. Ovulatory dysfunction, hyperandrogenism (clinical and/or biochemical) and polycystic ovarian morphology on ultrasound are the hallmark features of this condition and this is reflected in the diagnostic criteria employed by current International Guidelines.
...
Buy now
Presentation
Buy now
Diagnosis
Buy now
Investigations
Buy now
Management
Buy now
1.
Drake R, Vogl AW, Mitchell AWM. Gray’s Anatomy for Students E-Book: Elsevier Health Sciences; 2009.
Close
2.
Borgfeldt C, Andolf E. Transvaginal sonographic ovarian findings in a random sample of women 25-40 years old. Ultrasound Obstet Gynecol. 1999;13(5):345-50.
Close
3.
Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. East Melbourne, Victoria; 2016.
Close
4.
Royal College of Obstetricians and Gynaecologists, The British Society for Gynaecological Endoscopy. Management of Suspected Ovarian Masses in Premenopausal Women. RCOG/BSGE Joint Guideline. Report No.:62. [Internet]. 2011 [updated 2011 Nov 1].
Close
5.
The Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th ed. East Melbourne, Victoria: RACGP; 2018.
Close
7.
Yeoh M. Investigation and management of an ovarian mass. Aust Fam Physician. 2015;44(1-2):48-52.
Close
10.
Lux M, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med (Berl). 2006;84(1):16-28.
Close
11.
Rustin G, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996;7(4):361-4.
Close
12.
Sagi-Dain L, Lavie O, Auslander R, Sagi S. CA 19-9 in evaluation of adnexal mass: retrospective cohort analysis and review of the literature. Int J Biol Markers. 2015;30(3):e333-40.
Close
13.
Moore R, McKeein DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utlizing HE4 and CA 125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40-6.
Close
14.
Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97(10):922-9.
Close
15.
National Institute for Health and Care Excellence (NICE). Ovarian cancer: recognition and initial management. Report No.:CG122. [internet]. United Kingdom: NICE; 2011. Available from: https://www.nice.org.uk/Guidance/CG122.
Close
17.
Neesham D. Ovarian cancer screening. Aust Fam Physician. 2007;36(3):126-8.
Close
19.
Australian Government National Health and Medical Research Council. International evidence-based guideline for the assessment and management of polycystic ovary syndrome. Guidelines. Melbourne, Victoria; 2018.
Close
20.
Illingworth P. How to treat: Infertility. Australian Doctor. 2010;7(May):31-8.
Close
21.
Deeks A, Gibson-Helm ME, Paul E, Teede HJ. Is having polycystic ovary syndrome a predictor of poor psychological function including anxiety and depression? Hum Reprod. 2011;26(6):1399-407.
Close
22.
Coffey S, Mason H. The effect of polycystic ovary syndrome on health-related quality of life. Gynecol Endocrinol. 2003;17(5):379-86.
Close
23.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.
Close
24.
Lord J, Flight IH, Norman RJ. Metfomin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327(7421):951-3.
Close
